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A prostatic ductal adenocarcinoma is a variant of a prostatic
adenocarcinoma presumed to arise from or differentiate toward the
prostatic ductal epithelium.1 Morphologically, the tumor is char-
acterized by papillary, pseudostratiﬁed columnar, or cribriform
epithelial cells that are distinct from the cuboidal tumor cells seen
in a usual acinar adenocarcinoma of the prostate. Historically, this
variant was called an “endometrial” or “endometrioid” carcinoma
of the prostate due to the cytological and architectural growth
pattern superﬁcially reminiscent of an endometrial adenocarci-
noma.2 However, later immunohistochemical studies conﬁrmed its
prostatic origin instead of a Müllerian origin.3 Therefore, the term,
“endometrial” or “endometrioid” adenocarcinoma of the prostate
should be abandoned.2. Pathology
Grossly, prostatic ductal adenocarcinomas may grow as exo-
phytic lesions into the urethra, mostly in and around the ver-
umontanum, and they appear as polypoid or papillary tumors
indistinguishable from prostatic polyps or papillary urothelial
carcinomas cystoscopically.3 However, prostatic ductal adenocar-
cinomas frequently originate from the peripheral zone.4 The entity
should not be regarded as an exclusively centrally located neoplasm
developing from the large prostatic ducts of the transitional zone.
Microscopically, prostatic ductal adenocarcinomas manifest
a variety of morphologic features. The two most common patterns
are papillary and cribriform (Fig. 1). Less commonly, theymay show
single glands lined by tall columnar cells, resembling colorectal
adenocarcinoma, or with stratiﬁed columnar epithelium possessingl Hospital, 201 Shih-Pai Road,
ciation. Published by Elsevier Taiwcytologic and architectural features of a ﬂat and tufted high-grade
prostatic intraepithelial neoplasia (PIN), hence they have the
appellation of PIN-like ductal adenocarcinoma.5 Compared with
usual prostatic adenocarcinomas, prostatic ductal adenocarci-
nomas are more frequently associated with a desmoplastic stroma.
Although prostatic ductal adenocarcinomas can present as
a pure form, they more commonly coexist with a conventional
acinar adenocarcinoma. In most cases with mixed acinar and ductal
features, the two components intimately intermingle.6 In such
cases, designations such as mixed ductal and acinar adenocarci-
noma or adenocarcinoma with ductal and acinar features are
appropriate. In cases where the ductal component is a focal pres-
ence, the tumor should be diagnosed as an acinar adenocarcinoma
with focal ductal features.3. Gleason grading
The consensus regarding the histologic grading of a prostatic
ductal adenocarcinoma is that it is equivalent to Gleason pattern 4.
A prostatic ductal adenocarcinoma was suggested to be graded as
Gleason score 4 þ 4 ¼ 8 when it appears in a pure form.7 In mixed
formwith a usual prostatic adenocarcinoma, the ductal component
can be incorporated into the Gleason scoring system as grade 4, for
example, with a Gleason score of 4 þ 3 ¼ 7 in the case where
a predominant ductal adenocarcinoma admixes with a lesser
component of an acinar adenocarcinoma of Gleason pattern 3.4. Immunohistochemical ﬁndings
The immunohistochemical proﬁle of prostatic ductal adeno-
carcinomas is basically the same as that of acinar adenocarcinomas.
Tumor cells are usually immunoreactive for prostatic-speciﬁc
antigen (PSA; Fig. 2), prostatic acid phosphatase, prostatic-speciﬁc
membrane antigen, and alpha-methyl acyl-CoA racemase. It
should be noted that when the tumor is conﬁned within the
prostatic ducts, residual basal cells can be detected byan LLC. Open access under CC BY-NC-ND license.
Fig. 1. (A) Prostatic ductal adenocarcinoma showing the papillary and cribriform
growth pattern; (B) tall columnar epithelial lining with pseudostratiﬁcation of nuclei.
Fig. 2. Immunoreactivity for prostatic-speciﬁc antigen veriﬁes the prostatic origin of
the neoplasm.
C.-C. Pan / Urological Science 23 (2012) 87e8888immunostaining for high-molecular-weight cytokeratin and p63.8
Consequently, the patchy presence of basal cells among
neoplastic glands of this variant does not preclude a diagnosis of
a malignancy.
5. Treatment and prognosis
The biologic behavior of prostatic ductal adenocarcinomas is
generally comparable with usual acinar adenocarcinomas and
should be treated in a similar fashion. Nevertheless, most studies
demonstrated that the ductal morphology implies a more aggres-
sive course than for acinar prostate cancer.4 Prostate ductal
adenocarcinomas have comparable behaviors to adenocarcinoma
with a Gleason score of 4 þ 4 ¼ 8.
Since prostatic ductal adenocarcinomas can involve both the
transitional and peripheral zones, transurethral resection alone,which merely removes the transitional zone, is inadequate treat-
ment for this cancer. The presence of tumor foci on limited speci-
mens usually indicates a larger unsampled tumor within the
prostate. Only rarely is the tumor conﬁned within the transitional
zone and be extirpated by extensive transurethral resection. Urol-
ogists should be aware of the aggressiveness of this variant and
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